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Abstract: During persistent human beta-herpesvirus (HHV) infection, clinical manifestations may
not appear. However, the lifelong influence of HHV is often associated with pathological changes in
the central nervous system. Herein, we evaluated possible associations between immunoexpression
of HHV-6, -7, and cellular immune response across different brain regions. The study aimed to
explore HHV-6, -7 infection within the cortical lobes in cases of unspecified encephalopathy (UEP)
and nonpathological conditions. We confirmed the presence of viral DNA by nPCR and viral antigens
by immunohistochemistry. Overall, we have shown a significant increase (p < 0.001) of HHV antigen
expression, especially HHV-7 in the temporal gray matter. Although HHV-infected neurons were
found notably in the case of HHV-7, our observations suggest that higher (p < 0.001) cell tropism is
associated with glial and endothelial cells in both UEP group and controls. HHV-6, predominantly
detected in oligodendrocytes (p < 0.001), and HHV-7, predominantly detected in both astrocytes
and oligodendrocytes (p < 0.001), exhibit varying effects on neural homeostasis. This indicates a
high number (p < 0.001) of activated microglia observed in the temporal lobe in the UEP group. The
question remains of whether human HHV contributes to neurological diseases or are markers for
some aspect of the disease process.
Keywords: frontal lobe; temporal lobe; human herpesvirus 6; human herpesvirus 7; immune
response; PCR; immunohistochemistry
1. Introduction
Both human herpesvirus-6 (HHV-6) and human herpesvirus-7 (HHV-7) belong to
the Betaherpesvirinae subfamily [1,2]. The majority of the world’s population is exposed to
beta-herpesviruses (HHV) at the time of early childhood. Primary HHV infection causes
Roseola infantum, which rarely is severe, and infrequently is a fatal illness [3,4].
Human herpesviruses are capable of establishing lifelong persistence by an involve-
ment of different stages of the viral life cycle. During persistent viral infection, clinical
manifestations may frequently not even appear. However, the putative long term influ-
ence is associated with the central nervous system (CNS) diseases such as encephalitis,
Alzheimer’s disease, multiple sclerosis, and has a role in tumorigenesis and mood disor-
ders [5–16].
A wide range of endogenous and exogenous factors is implicated in the reactivation
of the virus, such as drugs and immunosuppression [17,18]. Host symbiosis with HHV can
be realized as 1) a latent phase when few viral genes are expressed, no virions and licensed
DNA synthesis can be detected, or 2) a lytic phase when most viral genes are expressed,
extracellular virions and unlicensed DNA are synthesized [19–21]. The host immune
system may regulate these fate-decisions concerning patterns of viral persistence [22,23].
Microglial cells are the dominant immune system cells of the CNS, providing the defense
against pathogens in case of injury or disease of the brain. [24–26].
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After crossing the body mucosal lining, HHV-6, -7 can enter potential replication
compartments in sensory ganglia [27,28]. Further, from ganglia via retrograde axonal
transport, herpesviruses can reach their target cells in the CNS [29,30]. This route may be
supplemented by another plausible pathway via the vascular system where viruses can
pass through the blood-brain barrier (BBB) to invade the brain parenchyma [12,31].
Previous studies of HHV-6, -7 have suggested their neurotropic nature and broad
neural cell tropism in vitro and in vivo [32–37]. Bending happens due to cell membrane
cofactor protein CD46 which is expressed on almost all cell types’ envelopes, viral gly-
coproteins that can form heterodimeric complexes to facilitate attachment and entry in
the host cell, and host cell membrane proteins [38–44]. Furthermore, both HHV-6A and
HHV-6B species have neuropathogenic pothential and capability to infect different neural
cell lines [1,45,46].
Despite current knowledge, neither the most affected brain areas nor the role of HHV-6,
-7 in the development of neurological disorders has been fully clarified [47]. The functional
brain tissue deficit is one of the features of biological aging as well, and the etiology of this
deficiency and its association with human beta-herpesviruses is still being studied.
Herein, we evaluated possible associations between immunoexpression of HHV-6, -7,
and cellular immune response across different brain regions. The study aimed to explore
and compare HHV-6, -7 infection within the gray and white matter of frontal and temporal
lobes in cases of unspecified encephalopathy vs nonpathological conditions. We tested for
the presence of viral DNA by nPCR and viral antigens by immunohistochemistry.
2. Results
2.1. Nested and Real Time Polymerase Chain Reactions
As a first step, both HHV-6 and -7 DNA were detected in 56.3% (27/48) of tissue
samples from all unspecified encephalopathy cases (UEP) (Table 1). Controls revealed
33.3% (16/48) samples with both HHV-6 and -7 DNA. In both UEP group and controls
HHV-6B was detected.
Table 1. The presence of single herpesvirus-6, 7 (HHV-6, -7) genomic sequences and HHV-6, -7 co-infection in tissue DNA
samples of the frontal and temporal lobes in the unspecified encephalopathy (UEP) individuals and control group.
Group Lobe










UEP Frontal 24 9 4 2 11 0.3759
Temporal 24 11 6 1 16 0.0209
Controls Frontal 24 4 4 0 8
Temporal 24 7 4 3 8
Further, in the UEP group, HHV-6 DNA was detected in 37.5% (9/24) and HHV-7
DNA – 16.7% (4/24) of the frontal lobe tissue samples. Concurrent HHV-6, -7 DNA was
detected in two frontal lobe tissue samples of this group. In the temporal lobe, HHV-6 DNA
was detected in 45.8% (11/24) and HHV-7 DNA in 25% (6/24) of UEP cases. Concurrent
HHV-6 and HHV-7 infection was detected just in one temporal lobe tissue sample of
this group.
In the control group, both HHV-6 and HHV-7 virus-specific sequences were revealed
in 16.7% (4/24) of the frontal lobe tissue samples, but in the temporal lobe, HHV-6 DNA
was detected in 29.2% (7/24), and HHV-7 DNA in 16.7% (4/24) of analysed samples.
Concurrent HHV-6 and HHV-7 infection was detected in three samples of this group.
HHV-6 and HHV-7 loads (> 10 copies/106 cells) were considered as elevated (PCR+).
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2.2. Immunohistochemistry
There was a small number of HHV positive neurons in both UEP group and controls.
Higher numbers of HHV-6, -7 positive cells were found in the frontal and temporal gray
matter compared to the white matter in both UEP group and controls; moreover, the highest




Figure 1. Pyramidal 3D surface plot represents the data of brain tissue immunohistochemical (IHC) analysis: total numbers
of herpesvirus -6, -7 (HHV-6, -7) positive cells in the white and gray matter of the unspecified encephalopathy (UEP) group
and controls. The blue plane represents a zero level (no virus-infected cells in the visual fields). Asterisks represent a
significance level between different groups (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; chi-square test for proportions).
In comparison with controls in both studied regions, the total number of HHV-6 posi-
tive glial cells in the UEP group’s gray and white matter was significantly higher (p < 0.001).
Further, there were significantly (p < 0.001) more HHV-6 positive oligodendrocytes in the
gray matter when compared to the white matter of given areas in the UEP group and
controls. A significantly (p < 0.001) increased number of HHV-6 positive endotheliocytes
was found especially in the gray matter of both frontal and temporal lobes in the UEP
group in comparison with controls (Table 2, Figure 2).
The total numbers of HHV-7 positive cells were significantly increased (p < 0.001)
in the gray and white matter of the temporal lobe in comparison with the frontal lobe of
the UEP group, also when compared to HHV-7 immunopositivity found in the controls
(Figure 2). A significant difference (p < 0.001) was found between the HHV-7 positive
oligodendrocytes located in the temporal and frontal gray matter of the UEP group. In the
UEP group, significantly (p < 0.001) higher numbers of HHV-7 positive astrocytes were
found in the gray matter of the temporal and frontal lobes in comparison with the white
matter, respectively (Table 2).
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Table 2. Numbers of herpesvirus-6, -7 (HHV-6, -7) immunopositive cells in tissue samples of the frontal and temporal lobes




























UEP Te HHV-6 10 32 33 122 148 345 30 42 89 79 240
Fr HHV-6 2 21 26 127 105 281 31 21 85 58 195
Te HHV-7 39 86 278 85 218 706 55 86 57 116 314
Fr HHV-7 27 87 257 33 115 519 49 76 15 89 229
Controls Te HHV-6 7 15 15 64 70 171 11 9 25 30 75
Fr HHV-6 0 7 15 43 47 112 10 9 35 15 69
Te HHV-7 10 18 42 44 184 298 12 30 26 61 129
Fr HHV-7 8 20 48 29 134 239 18 29 26 71 144
Legend: UEP—unspecified encephalopathy, Fr—frontal lobe, Te—temporal lobe, Neu—neurons, Mi—microglia, As—astrocytes, En—




Figure 2. Pyramidal 3D surface and violin plots representing the data of brain tissue immunohistochemical (IHC) analysis:
(A) total numbers of herpesvirus-6, -7 (HHV-6, -7) positive Neu (neurons), As (astrocytes), Ol (oligodendrocytes), Mi
(microglia), En (endotheliocytes) in the gray matter of the unspecified encephalopathy (UEP) group and controls, frontal
lobe (FR), temporal lobe (Te); (B) total numbers of HHV-6, -7 positive As (astrocytes), Ol (oligodendrocytes), Mi (microglia),
En (endotheliocytes) in the white matter of the UEP group and controls, frontal lobe (FR), temporal lobe (Te); (C) distribution
of total HHV-6 immunopositive endothelial cells per visual fields in the white (WM) and gray matter (GM) of the control
(Ctrl) and UEP group in the temporal and frontal lobe. The blue plane represents a zero level (no virus-infected cells in the
visual fields). Violin plots: dashed lines represent the approximate ratio of visual fields (out of 240) with HHV-6 positive
endotheliocytes to fields with HHV negative cells (“0”— ratio less than 1.0, “1”— more than 1.0); numbers in gray show
visual fields; asterisks represent a significance level (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001) between group
differences (Kruskal-Wallis test ).
Int. J. Mol. Sci. 2021, 22, 2364 5 of 18
Furthermore, based on nested polymerase chain reaction (nPCR) results, HHV posi-
tive tissue samples (PCR+) were analyzed using immunohistochemistry (IHC) (Table 3,
Figure 3).
Table 3. Numbers of herpesvirus-6, -7 (HHV-6, -7) immunopositive cells in the PCR+ tissue samples of the frontal and




























UEP Te HHV-6 10 24 28 70 124 256 20 39 61 63 183
Fr HHV-6 2 12 21 55 56 146 17 15 31 27 90
Te HHV-7 19 61 96 41 91 308 35 39 26 47 147
Fr HHV-7 19 36 66 18 41 180 24 24 10 18 76
Controls Te HHV-6 5 12 9 33 65 124 8 9 10 30 57
Fr HHV-6 0 1 7 23 36 67 2 7 12 8 29
Te HHV-7 3 6 20 7 56 92 1 2 4 11 18
Fr HHV-7 1 9 26 9 41 86 12 10 9 19 50
Legend: UEP—unspecified encephalopathy, Fr—frontal lobe, Te—temporal lobe, Neu—neurons, Mi—microglia, As—astrocytes, En—




Figure 3. Pyramidal 3D surface plots representing the data of immunohistochemical (IHC) analysis in the PCR+ samples:
numbers of herpesvirus-6, -7 (HHV-6, -7) positive Neu (neurons), As (astrocytes), Ol (oligodendrocytes), Mi (microglia), En
(endotheliocytes) in the gray (A) and white (B) matter of the unspecified encephalopathy (UEP) group and controls, frontal
lobe (FR), temporal lobe (Te). The blue plane represents a zero level (no virus-infected cells in the visual fields).
In the PCR+ samples, IHC results showed an increased number (p < 0.001) of HHV-6
positive oligodendrocytes in the gray matter of the frontal lobe in the UEP group when
compared to controls. An increased number (p < 0.001) of HHV-6 positive astrocytes in
the white matter of the temporal lobe in the UEP group was found when compared to
controls. The UEP group revealed no significantly increased HHV-6 positive endothelial
cells in the gray and white matter of the frontal lobe in comparison with controls, while in
the temporal lobe, an increased number of HHV-6 positive endothelial cells was found in
the white matter (Figure 4).
In the PCR+ samples, IHC results showed increased numbers (p < 0.001) of HHV-7
positive astrocytes and microglia in the gray and white matter of the frontal lobe in the
UEP group when compared to controls. The UEP group revealed a significantly increased
(p < 0.001) number of HHV-7 positive glial cells in the gray matter of the temporal lobe with
the most prominent positivity within astrocytes and oligodendrocytes ( Figure 5; Figure 6).




Figure 4. The presence of herpesvirus-6 (HHV-6) positive cells in the PCR+ samples: (A) detection 
of HHV-6 antigens by immunofluorescence, confocal microscopy (1000×), DAPI — blue, HHV-6 
immunopositive products — green. Left: frontal gray matter — HHV-6 positive neuron (arrow-
head), astrocyte (thick arrow), oligodendrocyte (narrow arrow) of the unspecified encephalopathy 
(UEP) subject; right: temporal gray matter — HHV-6 positive neuron (arrowhead), astrocyte (thick 
arrow), oligodendrocytes (narrow arrow) of the UEP subject; (B) detection of HHV-6 antigens by 
routine immunohistochemistry (IHC), HHV-6 immunopositive products — brown. Left: frontal 
gray (GM) and white (WM) matter of the UEP subject, neuron (arrowhead), astrocytes (thick ar-
row), oligodendrocytes (narrow arrow), (400×, 250×); right: temporal gray (GM) and white (WM) 
matter of the UEP subject, astrocytes (black thick arrow), oligodendrocytes (black narrow arrow), 
endotheliocytes (white thick arrow), (400×, 400×). 
In the PCR+ samples, IHC results showed increased numbers (p < 0.001) of HHV-7 
positive astrocytes and microglia in the gray and white matter of the frontal lobe in the 
UEP group when compared to controls. The UEP group revealed a significantly in-
creased (p < 0.001) number of HHV-7 positive glial cells in the gray matter of the temporal 
Figure 4. The presence of herpesvirus-6 (HHV-6) positive cells in the PCR+ samples: (A) detection
of HHV-6 antigens by immunofluorescence, confocal microscopy (1000×), DAPI—blue, HHV-6
immunopositive products—green. Left: frontal gray matter—HHV-6 positive neuron (arrowhead),
astrocyte (thick arrow), oligodendrocyte (narrow arrow) of the unspecified encephalopathy (UEP)
subject; right: temporal gray matter—HHV-6 positive neuron (arrowhead), astrocyte (thick arrow),
oligodendrocytes (narrow arrow) of the UEP subject; (B) detection of HHV-6 antigens by r utine
immunohistochemis ry (IHC), HHV-6 immunopositive products—brown. Left: frontal gray (GM)
and white (WM) matter of the UEP subject, neuron (arrowhead), astrocytes thick rro ), oligoden-
drocytes (narrow arrow), (400×, 250×); right: temporal gray (GM) and white (WM) matter of the
UEP subject, astrocytes (black thick arrow), oligodendrocytes (black narrow arrow), endotheliocytes
(white thick arrow), (400×, 400×).
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Figure 5. Violin plots representing the data of herpesvirus-7 (HHV-7) analysis in the PCR+ samples: 
(A) distribution of HHV-7 positive cells per visual fields in the gray and white matter of the control 
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(Ctrl) and unspecified encephalopathy (UEP) group, frontal lobe; (B) distribution of HHV-7 positive
cells per visual fields in the gray and white matter of the control (Ctrl) and UEP group, temporal
lobe; violin plots with dashed lines representing the approximate ratio of respective visual fields
with HHV positive cells to fields with HHV negative cells (“0”— ratio less than 1.0, “1”— more than
1.0); numbers in gray show visual fields; asterisks represent a significance level (* p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001; Mann-Whitney U-test).
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Figure 6. The presence of herpesvirus-7 (HHV-7) positive cells in the PCR+ samples: (A) detection 
of HHV-7 antigens by immunofluorescence, confocal microscopy (1000×), DAPI — blue, HHV-7 
immunopositive products — green. Left: frontal gray matter — HHV-7 positive neuron (arrow-
head), astrocyte (thick arrow), oligodendrocyte (narrow arrow) of the unspecified encephalopathy 
(UEP) subject; right: temporal gray matter — HHV-7 positive neuron (arrowhead), astrocyte (thick 
arrow), oligodendrocyte (narrow arrow) of the UEP subject; (B) detection of HHV-7 antigens by 
routine immunohistochemistry (IHC), HHV-7 immunopositive products — brown. Left: frontal 
gray (GM) and white (WM) matter of the UEP subject, astrocytes (black thick arrow), oligoden-
drocytes (black narrow arrow), vascular bed with positive mononuclear cell in the lumen (white 
thick arrow), (250×, 250×); right: temporal gray (GM) and white (WM) matter of the UEP subject, 
neuron (arrowhead), astrocytes (black thick arrow), oligodendrocytes (black narrow arrow), vas-
cular bed with positive mononuclear cell in the lumen (white thick arrow), (250×, 250×). 
Figure 6. The presence of herpesvirus-7 (HHV-7) positive cells in the PCR+ samples: (A) detection
of HHV-7 antigens by immunofluorescence, confocal microscopy (1000×), DAPI—blue, HHV-7
immunopositive products—green. Left: frontal gray matter—HHV-7 positive neuron (arrowhead),
astrocyte (thick arrow), oligodendrocyte (narrow arrow) of the unspecified encephalopathy (UEP)
subject; right: temporal gray matter—HHV-7 positive neuron arrowhead), astrocyte (thick arrow),
oligodendrocyte (narrow arrow) of the UEP subject; (B) detection of HHV-7 antigens by u ine
immunohistochemistry (IHC), HHV-7 immunopositive products—brown. Left: frontal gray (GM)
and white (WM) matter of the UEP subject, astrocytes (black thick arrow), oligodendrocytes (black
narrow arrow), vascular bed with positive mononuclear cell in the lumen (white thick arrow), (250×,
250×); right: temporal gray (GM) and white (WM) matter of the UEP subject, neuron (arrowhead),
astrocytes (black thick arrow), oligodendrocytes (black narrow arrow), vascular bed with positive
mononuclear cell in the lumen (white thick arrow), (250×, 250×).
An increased total number (p < 0.001) of CD68 positive cells was detected in the white
matter of the frontal and temporal lobes of the UEP group in comparison with controls
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(Table 4). Similarly, in the control cases, the placement of CD68 positive cells was more in
the white matter (p < 0.001) in comparison with gray matter.
Table 4. An arrangement of total CD68 positive cells in samples of the frontal and temporal lobes of
UEP individuals and control group.
Group Lobe













UEP Fr 314 466 780 1458 864 2322
Te 431 245 676 1289 376 1665
Controls Fr 273 193 466 901 323 1224
Te 284 185 469 842 233 1075
Legend: UEP—unspecified encephalopathy, Fr—frontal lobe, Te—temporal lobe, n– a number of CD68 positive
cells in the given areas.
In the UEP group and control cases, significantly more (p < 0.001) CD68 positive cells
with the diffuse arrangement in the white matter of both lobes were found. A similar
observation was made in the gray matter except for the UEP frontal lobe, wherein a
significantly increased (p < 0.001) number of perivascular CD68 positive cells was detected.
It is interesting that a significantly high (p < 0.001) increase in the number of CD68
positive cells was detected in the UEP temporal gray matter in comparison with the frontal
lobe.
Furthermore, based on nPCR results, the presence and location of CD68 positive cells
were analyzed in the PCR+ (both HHV-6 and HHV-7) and PCR negative (PCR-) samples
(Table 5).
Table 5. An arrangement of the total number of CD68 positive cells in the frontal and temporal lobes
of UEP individuals and control group comparing herpesvirus (HHV) PCR+ with HHV PCR- tissue
samples.
Group Lobe













UEP Fr_HHV+ 188 251 439 740 478 1218
Fr_HHV- 126 215 341 718 386 1104
Te_HHV+ 325 178 503 947 275 1222
Te_HHV- 106 67 173 342 101 443
Controls Fr_HHV+ 142 67 209 445 105 550
Fr_HHV- 131 126 257 456 218 674
Te_HHV+ 170 58 228 418 42 460
Te_HHV- 114 127 241 424 191 615
Legend: UEP—unspecified encephalopathy, Fr—frontal lobe, Te—temporal lobe, Fr_HHV+/T_HHV+ – HHV-6
and/or HHV-7 nPCR positive sample, Fr_HHV-/T_HHV- – HHV-6 and/or HHV-7 nPCR negative sample, n– a
number of CD68 positive cells in the given areas.
The highest total activated microglia/ macrophage numbers of the PCR+ UEP samples
in the temporal lobe were detected. In the HHV+ cases of the UEP group, an increased
number of diffuse located CD68 positive cells in the temporal areas, especially in the white
matter was detected (Table 5). In the HHV+ cases of the control group, an increased number
of diffuse located activated microglia/ macrophages in the gray matter was detected in
comparison with HHV- control cases, where the more perivascular organization of these
cells was found ( Figures 7 and 8).
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glia/macrophages (perivascular (thin arrows) and diffuse (thick arrows) location), (200×, 250×); 
right: temporal gray (GM) and white (WM) matter of the UEP subject demonstrating brown reac-
tion products in the activated microglia/macrophages (perivascular (thin arrows) and diffuse (thick 
arrows) location), (250×, 250×). 
There was a negligible number of lymphocytes in the white and gray matter of the 
UEP and control groups. Due to the low numbers of perivascular CD4 and CD8 positive 
cells, no significant associations between the pathological changes and HHV presence in 
all included cases were found. 
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Since the discovery of human beta-herpesviruses and their ability to persist lifelong 
in their hosts, augmented interest in the possible role of the virus in development of 
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nomic sequence was found in the UEP group, more precise data on HHV immunoloca-
tion were obtained by the immunohistochemistry. Remarkably, a significant increase in 
presence of HHV antigens, especially HHV-7, was detected in the temporal gray matter 
of the UEP group. This observation confirms earlier study reports on HHV findings in 
Fig re 8. Detection of CD68 positive cells by routine immunohistochemistry (IHC), CD68 im-
munopositive products brown. Left: frontal gray (GM) and white (WM) matter of the unspec-
ified encephalopathy (UEP) subject demonstrating brown reaction products in the activated mi-
croglia/macrophages (perivascular (thin arrows) and diffuse (thick arrows) location), (200×, 250×);
right: temporal gray (GM) and white (WM) matter of the UEP subject demonstrating brown reaction
products in the activated microglia/macrophages (perivascular (thin arrows) and diffuse (thick
arrows) location), (250×, 250×).
There was a negligible number of lymphocytes in the white and gray matter of the
UEP and control groups. Due to the low numbers of perivascular CD4 and CD8 positive
cells, no significant associations between the pathological changes and HHV presence in
all included cases were found.
3. Discussion
Since the discovery of human beta-herpesviruses and their ability to persist lifelong
in their hosts, augmented interest in the possible role of the virus in development of
neurodegenerative and mood diseases has been shown [6,15,16,47]. Our study used
autopsy materials of frontal and temporal cortical and subcortical areas of 48 individuals
ith and ithout (controls) diagnosis of unspecified encephalopathy.
By using co bined ethods it is possible to model complex relationships between
-6,-7 infected brain areas, and varied cell types that serve as reservoirs for the virus
it i the . I itiall , i o r st iral as etecte si t e tec i e.
rt er, I as se t t r i t r s c i tr c ll l r l c li ti f - ,
-7 proteins in the human brain tis ue.
r res lts sho e t at -6B D is co only found in brain tis ue
s l f i i i l it , as wel as in the control group. Although significantly
i creased frequency of H V-6 genomic sequenc in comparison with the HHV-7 genomic
sequenc was found in the UEP group, more recise data on HHV immunolocatio were
obtained by the immunohistochemistry. Remarkably, a significant increase i presence of
HHV antigens, especially HHV-7, was detected in th temporal gray matter of the UEP
group. This observation confirms earlier study repo t on HHV findi gs in the cerebral
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cortex, deep nuclei, and cerebellum [15,35,48]. Our previous study indicated more HHV-6
positive cells in the white vs gray matter of olfactory pathways [35,49]. However, also in
the present study, we observed significantly higher numbers of HHV-6, -7 positive cells
in the white matter of the UEP group vs controls. Although more HHV-6 positive neural
cells were detected in the gray matter of the UEP group, demonstrating the heterogeneity
of damage in the cortex vs subcortical white matter, however it does not preclude the
involvement of virus in changes of white matter in the earlier stage [11]. Our study findings
regarding increased numbers of HHV-6, -7 positive oligodendrocytes and astrocytes in
the temporal lobe support the hypothesis about viral infection as the causative agent of
neurodegenerative diseases [9,10]. Possibly, HHV-6, -7 contributes to the demyelination
process by the affection of oligodendrocytes in the white matter.
Despite our results suggesting that HHV-6, -7 may have a role in neurodegeneration,
an alternative possibility cannot be ruled out. Defects in cellular immunity can lead to
neurodegeneration, and this may result in the presence of persistent HHV-6, -7 [50,51]. The
presence of the virus can indicate a particular symbiosis between the virus and the host in
certain diseases [13,19]. It is not surprising to find HHV positive macrophages – monocyte
related cells with high affinity and well-known tropism for beta-herpesviruses [52]. Finally,
neural susceptibility to HHV-6, -7 may link to invalid cellular immune response, followed
by development of persistent viral infection.
As reviewed in detail elsewhere, the members of beta-herpesvirus subfamily can
activate and/or affect peripheral blood T lymphocytes and cells of the hematopoietic
lineage in vitro and in vivo [51,53,54]. Upon viral infection, immune system cells may
influence the switch between the lytic and latent phase, that way providing HHV symbiotic
machinery in the host organism [23]. Many studies support a role of CD8+ and CD4+ T
cells, immune mediators that are responsible for inhibiting viral replication [19,55,56]. We
found a low number of lymphocytes in contrast to monocytes-derived cells in the samples
included in our study. An increased number of activated microglial cells/macrophages
in the white matter of the frontal and temporal lobes of the UEP group vs controls was
detected. Furthermore, the highest expression of CD68 in the gray and white matter of the
temporal lobe in the HHV+ UEP cases was observed. It may be due to the requirement
for phagocytic cells in the pathogen rich region and pathological changes in the area [26].
Microglia can exert a direct antiviral effect showing phagocytic activities in the brain, as
reviewed by Chen and colleagues [25]. It is known that susceptibility to infection and the
chance of reactivation of dormant infectious agents increases when host defense abilities
decrease. One of the states, when this occurs, is when a person is getting older, so it was
meaningful to evaluate HHV-6, -7 expression in the gray and white matter of frontal and
temporal lobes of autopsy materials of the elderly. In the CNS, microglia are the resident
phagocytes of the innate immune system. Traditionally, microglia is regarded as a key to
the inflammatory process developing in response of nervous tissue to various harmful
influences. In this case, activated microglia can produce various proinflammatory cytokines
and immune mediators, thus creating a neurotoxic milieu leading to the progression of
diseases.
We found notably high numbers of HHV-6 infected endothelial cells, especially in
the temporal gray matter of the UEP group. Surprisingly, an increased number of HHV-7
positive vascular bed cells was found in the nPCR negative cases as well. The BBB is a highly
specialized structure consisting of both endothelial cells and astrocytes. These co-players
form a functional ‘neurovascular unit’ which has an essential role in the maintenance of a
normal CNS function [57]. It is known that astrocyte-endothelial cell interaction influences
the BBB in both physiological and pathological conditions [58]. It should be further
investigated whether the endothelial cells can retain the herpesvirus by concentrating it
in the vascular bed or, conversely, altered endotheliocytes can serve as a pathway for the
virus to enter the brain parenchyma.
Although we found herpesvirus-infected neurons, especially in the case of HHV-7,
our observations suggest that larger cell tropism is associated with glial and endothelial
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cells in both UEP group and controls and in accordance to Domingues et al. review can
modulate demyelination lesions [59]. As noted above, altered cell tropism to HHV found in
this study does not exclude the two herpesvirus pathways. The overall effect of concurrent
HHV-6 and -7 on brain tissue is still unclear, as there were few cases in our study.
Further experimental evidence is needed to focus on cell-derived inflammatory and
anti-inflammatory cytokines, bringing fundamental studies closer to clinical applicability
and finding a set of biomarkers for early diagnosis of changes in brain matter and viral
localization.
The main limitation of our research is the relatively low number of individuals in-
cluded in the UEP and control groups. We did not succeed in finding supplementary data
in the public data bases. Thus, larger groups are required in future to verify these results.
In order to obtain a comprehensive information on the inflammatory reaction in tissues, it
would be necessary to continue with a wider range of immunomarkers.
4. Materials and Methods
4.1. Tissue Material and Sampling
Brain autopsy samples from 24 unspecified encephalopathy (UEP) cases and 24 age-
matched cases without neuropathology (control group) were used in this study. In the UEP
group, brain autopsies from 16 males and 8 females (mean age 63.5 (range 42–76)), and
in the control group, age-matched 20 males and 4 females (mean age 61.4 (range 41–77))
were included.
In the UEP group, autopsies revealed an enlarged side and third ventricles, without
hemorrhagic or ischemic infarctions in the brain matter and without hemorrhagic changes
in the meninges. In the control group, pathomorphological unchanged brain autopsies
without dilated ventricles, hemorrhagic or ischemic infarctions in the brain matter and
without meningeal hemorrhagic changes were collected [60]. In the medical histories, no
clinical features were found regarding brain/neurological pathologies.
Cohorts of UEP and controls were de-identified after the death and before the con-
ventional autopsies. Tissue samples were obtained at the Department of Pathology, Riga
1st hospital, and the Latvian State Centre for Forensic Medical Examination. The post
mortem range between 7 and 30 hours was respected. Protocols for obtaining postmortem
brain tissue complied with all institutional guidelines with special respect for identity
confidentiality.
Within the framework of Latvian Council of Science Grant Nr.478/2012, the study pro-
tocol and the use of brain tissue autopsy samples were approved by the Ethics Committee
of Rı̄ga Stradin, š University (Decision of the RSU Ethics Committee No. 30/05/2013) on 30
May 2013.
4.2. Nested and Real Time Polymerase Chain Reactions
Nested polymerase chain reaction (nPCR) for the qualitative detection of HHV-6, -7
genomic sequences in DNA isolated from fresh frontal and temporal lobe samples was
used. Total DNA was isolated from tissue samples using standard phenol-chloroform
extraction. To ensure the quality of extracted DNA, a β-globin PCR was performed. PCR
amplification for the HHV-6, -7 was conducted using 1 µg of the tissue DNA [60].
Primers complementary to the U3 gene that encodes main capsid proteins for both
HHV-6A and HHV-6B and U10 gene for HHV-7 were used. Positive controls (HHV-6 and
HHV-7 genomic DNA; ABI, Columbia, MD, USA) and negative controls (DNA obtained
from practically healthy HHV-6 and HHV-7 negative blood donors), as well as water
controls were included in each experiment.
Presence of HHV-6 U3 gene sequence was detected using the following primers: Cycle
1: HV1 forward-5’- GCGTTTTCAGTGTGTAGTTCGGCAG- 3’
HV2 reverse- 5’- TGGCCGCATTCGTACAGATACGGAGG- 3’
Cycle 2: HV3 forward- 5’- GCTAGAACGTATTTGCTGCAGAACG- 3’
HV4 reverse- 5’- ATCCGAAACAACTGTCTGACTGGCA- 3’
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Presence of HHV-6 LTP gene sequence was detected with the following primers:
Cycle 1: O1 - 5′- AGTCATCACGATCGGCGTGCTATC- 3′
O2 - 5′-TATCTAGCGCAATCGCTATGTCG-3′
Cycle 2: I3 - 5′-TCGACTCTCACCCTACTGAACGAG- 3′
I4 - 5′-TGACTAGAGAGCGACAAATTGGAG- 3′
Obtained nPCR amplification products were digested with HindIII restriction endonu-
clease (Thermo Scientific, USA) which cleaves HHV-6B 163 bp amplification product into
66 bp and 97 bp fragments, whereas does not cleave HHV-6A.
Presence of HHV-7 U10 gene sequence was detected using the following primers:
Cycle 1: HV7 forward- 5’ – TATCCCAGCTGTTTTCATATAGTAAC – 3’
HV8 reverse- 5’ – GCCTTGCGGTAGCACTAGATTTTTTG – 3’
Cycle 2: HV10 forward- 5’ – CAGAAATGATAGACAGATGTTGG – 3’
HV11 reverse- 5’ – TAGATTTTTTGAAAAAGATTTAATAAC – 3’
Real-Time PCR with the β-globine gene as an internal control was performed. HHV-6
load was determined with HHV-6 Real-TM Quant (Sacace Biotechnologies, Italy). The
test contains an IC (β-globine gene), which serves as an amplification control for each
individually processed specimen and to identify possible reaction inhibition.
HHV-7 load was detected using REALQUALITY RS-HHV 7 kit (AB ANALITICA
Advanced biomedicine, Padua, Italy) with the β-globine gene as an internal control or using
Human Herpes Virus 7 genomes genesig kit (Primerdesign, Eastleigh, United Kingdom),
also with an internal control.
HHV-6 and HHV-7 loads (> 10 copies/106 cells) were considered as elevated. Detec-
tion of HHV-6 and -7 DNA was done following Secchiero and Berneman et al. [61,62].
4.3. Immunohistochemistry
Anti-HHV-6 (20) mouse monoclonal IgG, raised against viral lysate for immunohisto-
chemical (IHC) detection of HHV-6A and HHV-6B (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA, 1:200), anti-HHV-7 antibody raised against the tegument protein pp85 of
HHV-7 (Advanced Biotechnologies, Columbia, MD, USA, 1:500) were used for detection of
virusspecific antigene expression, and CD68 mouse monoclonal antibody (Cell Marque,
Rocklin, CA, USA, clone Kp-1, 1:200) for detection of activated microglia/macrophages
in brain tissue samples. For quantitative analysis of immune system cells in the autopsy
material, anti CD4 (Cell Marque, Rocklin, CA, USA, clone SP35, 1:100) and anti CD8 (Cell
Marque, Rocklin, CA, USA, clone C8/144B, 1:100) mouse monoclonal antibodies were
used. The myelin basic protein (MBP, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA,
clone 1.B.645, 1:150) and glial fibrillary acidic protein (GFAP, Novocastra, Leica Biosystems,
Newcastle, UK, clone GA5, 1:100) was used to detect oligodendrocytes and astrocytes,
respectively. For all the reactions negative controls were performed replacing the primary
antibodies with a PBS solution. For positive controls, tissue samples from osteoarthritis
and rheumatoid arthritis cases with HHV+ detected by nPCR, and with known antibody
positivity were used. Representative figures are added in the supplement (Figure S1).
Brain tissues were prepared in accordance with the standard histopathology proto-
col, followed by immunohistochemistry and fluorescence microscopy as described pre-
viously [63]. Paraffin-embedded 4–5 µm histological sections were deparaffinized and
hydrated in xylene and series of graded ethanol, respectively. The activity of endogenous
peroxidase was reduced by 30% hydrogen peroxide in methanol (30 min). Antigen retrieval
was performed in 0.01 M citrate buffer (15 min) at 96 ◦C. Following the manufacturer’s
recommendations, sections were incubated overnight (4 ◦C) with the primary antibodies.
HiDef Detection™ HRP Polymer system (CellMarque, Rocklin, CA, USA) was used for
visualization of antigen–antibody complexes. Sections were successively incubated with
HiDef Detection™ Amplifier for 10 min (RT) and HiDef Detection™ HRP Polymer Detec-
tor for 10 min (RT) after rinsing in phosphate-buffered saline (PBS). The antigens were
visualized by 3,3’ diaminobenzidine (DAB) tetrahydrochloride kit (DAB+Chromogen and
DAB+Substrate buffer, Cell Marque, Rocklin, CA, USA) for 5 min. Thereafter, sections
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were stained by Mayer’s hematoxylin, rinsed with tap water, dehydrated, cleared, and
embedded in Roti®Histokitt (Carl Roth, Karlsruhe, Germany).
Antigen expression was assessed quantitatively by counting the number of immunopos-
itive cells.
Expression of antigens was estimated in 10 randomly selected vision fields of each sam-
ple at ×400 magnification using a Leica light microscope (LEICA, LEITZ DMRB, Germany)
and Glissando Slide Scanner (Objective Imaging Ltd., Cambridge, UK). Duplicable mea-
surements of tissue markers were obtained, including gray and white matter of the frontal
and temporal lobes using Aperio ImageScope program v12.2.2.5015 (Leica Biosystems,
Buffalo Grove, IL, USA).
For immunofluorescence, after immunostaining with the primary antibody, sections
were washed with PBS buffer (3 × 5 min), and then with secondary goat anti-mouse
IgG (H+L) antibody, Alexa Fluor®488 conjugate (Thermo Fisher Scientific, Invitrogen, UK,
1:300) was applied. The tissue staining with 4′,6-diamidino-2-phenylindole (DAPI) (Thermo
Fisher Scientific, Invitrogen, UK, 1:3000) was performed to analyze the arrangement of
cell nuclei. After that, sections were embedded in Prolong Gold with DAPI (Thermo
Fisher Scientific, Invitrogen, UK). Before the coverslipping, the autofluorescence effect was
minimized using 0.2% Sudan Black B solution (Sigma Aldrich, St. Louis, MO, USA). All
immunofluorescence images were captured using a Nikon confocal microscope Eclipse
Ti-E (Nikon, Brighton, MI, USA).
4.4. Data Analysis
Numerical data distribution of nPCR and IHC results was analysed by the D’Agostino
and Pearson, Anderson–Darling, and Shapiro–Wilk normality tests. Different groups of
numerical variables were compared by one-way ANOVA or one-way ANOVA on ranks
and Kruskal–Wallis test followed by a two-stage step-up method of Benjamini, Krieger, and
Yekutieli as a post hoc test. Brown-Forsythe and Bartlett’s tests were applied for testing the
homogeneity of variances. For categorical variables, the chi-square test was performed. For
the comparison of numerical values between two groups, the two-tailed Mann-Whitney
U test was applied. IHC results are expressed as violin plots, and a p-value less than 0.05
(p < 0.05) was considered statistically significant. In violin plots, the medians (visualized
as dashed lines) were used to represent the approximate ratio of visual fields (max out of
240) with HHV-positive cells to fields with HHV-negative cells (“0” – ratio less than 1.0, “1”
– more than 1.0).
All the graphs, calculations, and statistical analyses were performed using the program
GraphPad Prism 9 (GraphPad Software, La Jolla, CA, USA).
5. Conclusions
Our results suggest that HHV-6 and -7 may have a role in the brain micro-environment.
Or perhaps, an alternative possibility is if brain parenchyma is characterized by defects
in cellular immunity, it may lead to the persistence of HHV-6 and/or -7 in some kinds of
brain cells.
HHV-6, predominantly located in oligodendrocytes, and HHV-7, predominantly
located in astrocytes and oligodendrocytes, exhibit greatly varying effects on neural home-
ostasis, although there is no evidence of viral replication. A high number of activated
microglia observed in the temporal areas in the UEP group serves as an indicator of the
cellular immune response to HHV. The HHV antigens found in endotheliocytes suggest
that BBB is involved in the spread of HHV. Analysis of HHV-positive cell distribution
reveals a causal role of the virus in healthy and changed conditions. The question remains
of whether the human beta-herpesviruses contribute to the neurological diseases or are
markers for some aspect of the disease process. Because of the conflicting results in the
medical literature regarding the role of HHV-6 and HHV-7 infection in the development of
neurologic diseases, further research should be performed to confirm or deny the direct
causality of neurologic disorders due to herpesvirus -6, -7 in the human brain.
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